2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

908. Outcomes Research: Myeloid Malignancies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Transplantation, Non-Biological Therapies, Anticoagulant Drugs, Chemotherapy, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Natural Language Processing, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Genetic Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, MDS, MPN, CML, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2835 Incidence and prevalence estimates of patients with acute myeloid leukemia (AML) by relapsed/refractory and fitness status in the United States

Laura Hester, PhD, MSc, Xiaojian Chen2, Tara Beaulieu, PhD, MIPH3, Kathryn Bradford, MD4, Dina Gifkins, PhD, MPH5
1 Johnson & Johnson, Horsham, Pennsylvania, United States
2 Johnson & Johnson, Potomac, Maryland, United States
3 Johnson & Johnson, Raritan, New Jersey, United States
4 Johnson & Johnson, Spring House, Pennsylvania, United States
5 Johnson & Johnson, Raritan, New Jersey, United States

Background: Published United States (US) estimates of incidence and prevalence of clinically relevant acute myeloid leukemia (AML) subpopulations remain limited. This study used a contemporary US real-world cohort with AML to estimate fitness status for intensive treatment, transition to R/R AML, and survival after R/R AML, subsequently applying these estimates to US cancer registry data to estimate US AML incidence by fitness status and US R/R AML prevalence in 2023.

Methods: Real-world AML data were obtained from the COTA/Verana Vantage AML database, which includes structured and unstructured electronic health record data from US oncology clinics, and from the US Surveillance, Epidemiology, and End Results (SEER) Program cancer registries. AML was defined using ICD-O-3 morphology codes. Based on a published proxy, fitness status for intensive treatment was approximated using Eastern Cooperative Oncology Group (ECOG) performance status and age, with fit defined as ECOG 0–1 and age <78 years and unfit defined as ECOG 2–4 at any age or age ≥78 years. Lines of therapy and progression used to define R/R AML were determined using a National Comprehensive Cancer Network (NCCN)-based AML treatment algorithm adapted for the COTA/Verana database. Using the COTA/Verana AML data, fitness status distributions were estimated for patients with newly diagnosed AML (2023-2025) and patients initiating second-line therapy during 2023-2025 after a new AML diagnosis from 2018-2025. Percentages by fit status for newly diagnosed AML were applied to the US 2023 incidence of AML from the SEER 21 registries. R/R AML prevalence was estimated by multiplying the 2023 SEER AML incidence by the COTA/Verana-derived proportion of patients transitioning to R/R AML and median survival after R/R AML in 2018-2025.

Results: Among 457 contemporary patients newly diagnosed with AML in COTA/Verana from 2023-2025, 327 patients had ECOG data for assigning fitness status; of these patients, 195 (60%) were classified as fit for intensive treatment, and 132 (40%) as unfit. Applying these proportions to the 2023 SEER age-adjusted AML incidence rate of 4.4 per 100,000 persons yielded estimated incidence rates of 2.62 and 1.78 per 100,000 persons for fit and unfit patients with newly diagnosed AML, respectively. Among 274 patients with newly diagnosed AML who reached second-line therapy in the COTA/Verana database from 2023-2025, approximately 67% were classified as fit, with 33% remaining unfit. Using the SEER incidence estimate of 4.4 per 100,000 persons multiplied by the COTA/Verana-derived proportions of patients with R/R AML (0.69) and median overall survival following progression to R/R AML (0.82 years), the estimated US prevalence count of R/R AML was 7,703 patients in 2023.

Conclusion: These analyses provide novel real-world estimates of US AML incidence by fitness status for intensive treatment and the prevalence of R/R AML. In the contemporary US real-world AML cohort, 40% of patients with newly diagnosed AML and 33% of patients initiating second-line therapy were classified as unfit, indicating that a substantial proportion of patients have clinical characteristics that may limit use of intensive AML regimens. When COTA/Verana-derived estimates were applied to SEER incidence data, the estimated 2023 US AML incidence was 2.62 and 1.78 per 100,000 persons among fit and unfit patients, respectively, and the estimated prevalence of R/R AML was 7,703 patients, underscoring the continued population-level burden of clinically relevant AML subgroups. Collectively, these results support the need for continued therapeutic innovation and evidence generation to address the unmet needs of patients with AML, particularly those who are unfit for intensive treatment.

Laura Hester, PhD, MSc: Johnson & Johnson - Current equity holder in publicly-traded company; Johnson & Johnson - Stock (publicly traded); Johnson & Johnson - Current Employment